Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Oriola

0.76 EUR-3.08 %7.10, 17.29
7,769 following

ORIOLA

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor views
Compare
-3.08 %
-16.00 %
-21.33 %
-20.67 %
-34.26 %
-33.10 %
-17.29 %
-57.19 %
-58.90 %

Oriola is a pharmaceutical group with a particular focus on the distribution of pharmaceuticals to other players in the industry. The company offers services to pharmacies and other pharmaceutical companies, which includes, for example, negotiations with suppliers and distribution of products. The largest operations are in the Nordic and Baltic regions. The headquarters are located in Espoo.

Read more
Market cap
140.11M EUR
Turnover
235.41K EUR
P/E (adj.) (26e)
15.61
EV/EBIT (adj.) (26e)
1.51
P/B (26e)
1.5
EV/S (26e)
0.16
Dividend yield-% (26e)
3.97 %
Coverage
Recommendation
Reduce
Target price
0.80 EUR
Updated
05.10.2026
Disclaimer
Rauli Juva
Rauli Juva

Analyst

Latest research

Latest analysis report

Released: 05.10.2026

Latest extensive report

Released: 23.06.2026

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
Päädyin tosiaan siirtymään vähennä-puolelle tässä, vaikka kurssi taitaa olla kaikkien aikojen pohjissa, ja selkeästi yhtiössä pitäisi olla potentiaali parempaan / korkeampaan arvoon. Lähivuosien riskit vaan painavat nyt mielestäni enemmän kuin mahdollinen potentiaali, joka todenn...
10/5/2026, 6:44 AM
by Rauli_Juva
15
Nykyinen toimitusjohtaja on toiminut n 4 vuotta hommassaan. Sitä ennen pitkä ura Oriolalla muissa tehtävissä. Sanoisin että osaaminen alkaa olla nyt nähty ja olisi aika (taas kerran) etsiä joku joka oikeasti saisi tämän katastrofifirman kuntoon. Käsittämättömän kauan on yritetty ...
10/1/2026, 7:09 AM
by TitoK
14
Tuntuu jokseenkin mahdottomalta, että Gabrielsson voisi jatkaa kovin pitkään tämän jälkeen Oriolan johdossa. Aiemman valtakunnan uutisiin päätyneen ERP-sotkun takia tämänkertaisen hankkeen on täytynyt olla erityisen tarkassa seurannassa ja silti se onnistuttiin ryssimään sekä aikataulun...
10/5/2026, 6:47 AM
by mikde
12
This really is something burned my own fingers with Oriola years ago. You could definitely make a good case study out of this Oriola thread, or one of those “investing lessons learned the hard way.” Let me break it down a bit: Macroeconomics provides favorable tailwinds (growing ...
10/2/2026, 11:05 AM
by Saunatonttu
12
Here are some comments on that, the price tag of the delay is truly shocking. At the same time, the partner changed, which of course indicates that the beginning of the project did not go as desired and partly explains the additional costs. But it’s better to pay these costs at this...
10/1/2026, 6:26 AM
by Rauli_Juva
11
Only now catching up after work to see why Oriola is dropping on the stock market… How can running such a rock-solid business be this difficult?!? In practice, Oriola only has one competitor, Tamro. And this business isn’t rocket science—you handle pharmaceutical logistics. The current...
10/1/2026, 3:02 PM
by Lohis
10
Eipä ole tullut vuosikausiin seurattua firmaa kun oli uudet systeemit ja jakelut ryssitty huolella.Ja mitä ihmettä, katsoin että osake laskee että mikä nyt, niin samaa sohloomista vuodesta toiseen.Tehkää Woltin kanssa diili, niin sekin sujuu paremmin Hyvästi!
10/1/2026, 7:22 AM
by Raikku
7
Read more on our forum
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
29.10
2026

Interim report Q3'26

23.2
2027

Annual report '26

24.3
2027

General meeting '27

Oriola, Webcast, Q3'26
Webcast29.10.2026, 09.00

Oriola, Webcast, Q3'26

Oriola
Oriola: Risks weigh on the coming years
Research05.10.2026, 07.34 by
Rauli Juva

Oriola: Risks weigh on the coming years

The prolonged IT system renewal means that, in our view, a sustainable earnings improvement will only be possible by 2029.

Oriola
Oriola: Forsinkelse af ERP-opdatering medfører væsentlige ekstraomkostninger
Analyst Comment01.10.2026, 08.20 by
Rauli Juva

Oriola: Forsinkelse af ERP-opdatering medfører væsentlige ekstraomkostninger

En ekstra regning på knap 20 MEUR og en forsinkelse af ERP-projektet til 2028 reducerer de rapporterede resultatestimater.

Oriola

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release01.10.2026, 07.30

Oriola Oyj: Oriola updates timeline and investment of ERP and warehouse management programme

Oriola
Regulatory press release24.09.2026, 11.15

Correction: Oriola Corporation: Notification of a change in shareholding according to Chapter 9, Section 10 of the Securities Market Act

Oriola
Regulatory press release23.09.2026, 16.00

Oriola Corporation: Notification of a change in shareholding according to Chapter 9, Section 10 of the Securities Market Act

Oriola
Regulatory press release18.09.2026, 08.00

Oriola Oyj: Oriola has corrected previously reported financial information

Oriola
Regulatory press release17.09.2026, 08.00

Oriola Oyj: Publication schedule for Oriola Corporation's financial reporting in 2027

Oriola
Oriola Q2'26: Træg udvikling
Research20.07.2026, 06.25 by
Rauli Juva

Oriola Q2'26: Træg udvikling

Vi estimerer, at selskabet med nød og næppe vil nå sin udmeldte resultatforbedring for hele året.

Oriola
Oriola Q2'26: Headwinds from higher freight costs6:42
Video17.07.2026, 11.42 by
Rauli Juva

Oriola Q2'26: Headwinds from higher freight costs

Higher freight costs and increased operating expenses weighed on Oriola's earnings in Q2. Meanwhile, associate company Kronans improved its result compared with the corresponding period last year.

Oriola
Oriola, Webcast, Q2'26
Webcast17.07.2026, 09.00

Oriola, Webcast, Q2'26

Oriola
Oriola Q2'26 - kort kommentar: Resultatet var på niveau med sammenligningsperioden
Analyst Comment17.07.2026, 08.05 by
Rauli Juva

Oriola Q2'26 - kort kommentar: Resultatet var på niveau med sammenligningsperioden

Oriolas Q2-regnskab var operationelt en smule svagere end vores forventninger, da selskabets justerede EBITDA forblev på niveau med sammenligningsperioden og var lidt lavere end vores estimater.

Oriola
Regulatory press release17.07.2026, 07.30

Oriola Oyj: Oriola Corporation's Half-Year Report 1 January-30 June 2026

Oriola
Oriola Q2'26 preview: Moderat indtjeningsvækst
Analyst Comment07.07.2026, 07.00 by
Rauli Juva

Oriola Q2'26 preview: Moderat indtjeningsvækst

Vi estimerer, at den justerede EBITDA vil stige en smule til 8,5 MEUR som følge af resultatforbedringen i Products-segmentet.

Oriola
Press release03.07.2026, 08.00

Oriola Oyj: Oriola Corporation to publish its Half-Year Report for January-June 2026 on 17 July 2026

Oriola
Oriola Extensive Report: Patience prescribed
Extensive research23.06.2026, 11.15 by
Rauli Juva

Oriola Extensive Report: Patience prescribed

Oriola's stock looks cheap, but there are clear risks associated with both the balance sheet and operational activities.

Oriola
Regulatory press release12.06.2026, 16.00

Oriola Oyj: Oriola's share buyback programme has been completed

Oriola
Regulatory press release10.06.2026, 18.00

Oriola Oyj: Acquisition of own shares during week 24, 2026

Oriola
Regulatory press release10.06.2026, 14.30

Oriola Oyj: Composition of Oriola Corporation's Shareholders' Nomination Board

Oriola
Regulatory press release05.06.2026, 18.00

Oriola Oyj: Acquisition of own shares during week 23, 2026

Oriola